Millennium Pharmaceuticals (MLNM) 10-K2005 FY Annual report

Filed: 8 Mar 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: advantage, Aggregometer, Anna, anthony, Asia, attrition, Bianchi, blended, broadly, carboplatin, certainty, chain, Christophe, commentary, compensatory, confidence, Consent, context, Covanta, crystalline, Deborah, diversified, duly, Dunsire, efficient, eric, erlotinib, Ernst, escrowed, estate, exhibit, expeditiously, fierce, friel, Gansler, gemcitabine, glycoprotein, heidrich, hematolic, highest, homcy, http, IIa, inapplicable, interruption, JJPRD, kucherlapati, lander, Latin, leader, lenalidomide, lifetime, LLP, MA, matched, norman, NSCLC, omitted, pemetrexed, preceding, prelaunch, promptly, raju, randomized, real, receipt, refine, refined, refinement, regimen, requisite, rituximab, Rorer, Sandoz, Sangstat, selby, settle, settlement, Southwest, stake, Stephen, strength, subset, successor, Synta, technical, thereunto, TransForm, unchanged, undergone, undersigned, unsuitable, USA, weg, wild, Young

Removed: abide, added, administer, Africa, announcement, antidilutive, antigen, Argentina, assuming, block, Brazil, breast, Bulletin, BZL, CDC, chemotherapeutic, clinician, collaborative, communicate, complement, conclusion, confidentiality, conjugated, consulting, contracted, converted, coupled, defer, dilutive, diverse, eventual, extra, facility, feasibility, FIN, formulary, Genentech, Greek, heart, hospital, improve, improvement, inclusion, incomplete, India, initiative, involving, Linda, Mayfield, mechanism, membrane, Mexico, Monsanto, noncash, ovarian, partner, pharmacy, Pine, prescribing, prostate, protein, PSMA, pursuing, ratio, realign, regional, Singapore, specialty, sponsored, summer, survey, Switzerland, targeting, Thailand, top, urology, vehicle, viral

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MLNM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

STATEMENT PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Annual Report on Form 10-K for the period ended December 31, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Millennium Pharmaceuticals, Inc.

		/s/ DEBORAH DUNSIRE
Dated: March 8, 2006		Deborah Dunsire
		President and Chief Executive Officer
		(Principal executive officer)

A signed original of this written statement required by Section 906 has been provided to Millennium Pharmaceuticals, Inc. and will be retained by Millennium Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.